The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of ingredients that outsourcing pharmacies can use to make bulk drug products. This change would prevent compounding pharmacies from manufacturing cheaper generic versions of these weight-loss and diabetes drugs.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Move would bar outsourcing facilities from compounding bulk versions of these drugs
• •Targets cheaper compounded alternatives to branded weight-loss and diabetes drugs

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can bulk-order for compounding (making custom doses). This would force patients to use brand-name versions of these weight-loss and diabetes drugs instead of cheaper pharmacy-made copies.

• •FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulks list
• •Move would block pharmacies from bulk-ordering these APIs for compounding
• •Patients would be pushed toward brand-name versions

The FDA plans to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that large-scale pharmacies can legally make in bulk (called 503B compounding). This change would force patients to buy these weight-loss and diabetes drugs from manufacturers instead of cheaper pharmacy-made versions.

• •FDA plans to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
• •Move would block large-scale pharmacy bulk compounding of these GLP-1s
• •Patients would need to source from manufacturers rather than compounded versions

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can use to make bulk copies under 503B rules (a program that lets facilities make custom medicines). This change would prevent large-scale compounding of these weight-loss and diabetes drugs, likely pushing patients toward branded versions.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Change would block large-scale compounding of these GLP-1 drugs
• •Patients would be pushed toward branded versions

Health Canada approved the first generic version of semaglutide (Ozempic), Novo Nordisk's popular diabetes and weight-loss drug. This means Canadian patients may soon have access to a cheaper alternative to the brand-name version.

• •Health Canada approved the first generic version of Ozempic (semaglutide).
• •Approval covers Novo Nordisk's diabetes and weight-loss drug.
• •Canadian patients may gain access to a cheaper alternative to the brand.

Novo Nordisk is lowering the advertised U.S. prices for Ozempic (a diabetes drug) and Wegovy (a weight-loss drug) by as much as 50%. This is the company's move to make these expensive medications more affordable for patients and insurers.

• •Novo Nordisk to cut US list prices for Ozempic and Wegovy by up to 50%
• •Move targets affordability for patients and insurers

The FDA is taking steps to permanently ban pharmacies from making compounded versions of GLP-1 drugs (weight-loss and diabetes medications like semaglutide). This could force patients to buy more expensive brand-name versions instead of cheaper pharmacy-made copies.

• •FDA moving to permanently bar pharmacies from compounding GLP-1 drugs
• •Action targets compounded versions of semaglutide and related GLP-1s
• •Patients would be pushed toward more expensive brand-name products

Apotex, a Canadian drugmaker, got approval from Health Canada to sell a generic copy of Ozempic (semaglutide), a popular weight-loss and diabetes medicine. This is the first generic version approved by Canada's health regulator.

• •Apotex received Health Canada approval for a generic equivalent of Ozempic (semaglutide)
• •First Canadian-based pharma company to win generic Ozempic approval in Canada

Canada approved a generic version of semaglutide (the active ingredient in Ozempic) made by Dr. Reddy's Laboratories. This generic copy is cheaper and could give more people access to the weight-loss and diabetes drug.

• •Canada approved Dr. Reddy's generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic
• •Generic is cheaper and aims to broaden access for diabetes and weight loss

Dr. Reddy's Laboratories received approval from Health Canada to sell a generic version of semaglutide injection in Canada. This is the first generic copy of the popular weight-loss and diabetes drug to be approved there.

• •Dr. Reddy's received Health Canada approval for generic semaglutide injection
• •First generic semaglutide approved in Canada
• •Approval covers weight-loss and diabetes indications

Canada's health authority approved the first generic copy of semaglutide (Ozempic), the popular weight-loss and diabetes drug. This approval means cheaper versions of the medicine may become available as more companies compete to make GLP-1 drugs.

• •Canada approved the first generic version of semaglutide (Ozempic)
• •Approval opens the door to cheaper GLP-1 alternatives in Canada
• •Decision arrives amid rising competition in the GLP-1 class

Canada approved a generic version of semaglutide, the active ingredient in Ozempic. This means Canadian patients may have access to a cheaper alternative to the brand-name weight-loss and diabetes drug.

• •Canada approved a generic version of semaglutide, the active ingredient in Ozempic.
• •Generic entry positions Canadian patients for a cheaper alternative to brand-name Ozempic.

The FDA has signaled it will not add popular GLP-1 drugs (like semaglutide, a weight-loss medicine) to the 503B list, which allows certain pharmacies to make bulk copies of medicines. This decision means patients will likely need to rely on brand-name versions of these drugs rather than cheaper pharmacy-made alternatives.

• •FDA signals it will not add popular GLP-1 substances to the 503B bulks list
• •503B listing would have allowed outsourcing facilities to compound bulk GLP-1 copies
• •Patients likely steered back to brand-name GLP-1s over compounded alternatives

Canada's health regulator approved a second generic copy of semaglutide (Ozempic), the popular diabetes and weight-loss drug made by Novo Nordisk. More generic options could help lower costs for patients in Canada.

• •Canada's health regulator approved a second generic version of semaglutide (Ozempic)
• •Ozempic is made by Novo Nordisk
• •More generic options could help lower costs for patients in Canada

Canada's health authority approved a second generic version of semaglutide (Ozempic), the popular weight-loss and diabetes drug. More generic copies available could lower prices and help more people afford the medicine.

• •Canada approved a second generic version of semaglutide (Ozempic)
• •Additional generics expected to lower prices and broaden access

Health Canada approved a second generic version of semaglutide (the active ingredient in Ozempic), made by a Canadian company. This gives patients another cheaper alternative to the brand-name weight-loss and diabetes drug.

• •Health Canada approved a second generic version of semaglutide
• •The generic is manufactured by a Canadian company
• •Ozempic is Novo Nordisk's branded semaglutide for diabetes and weight loss

Canada approved a second generic version of Ozempic (a semaglutide injection used for diabetes and weight loss). This expands access to cheaper copies of the drug beyond Novo Nordisk's brand-name version.

• •Canada approved a second generic version of Ozempic (semaglutide injection)
• •Generic is indicated for diabetes and weight loss
• •Approval adds a second copycat competing with Novo Nordisk's brand

Canada has approved a second generic copy of semaglutide (the drug in Ozempic). This means more affordable versions of the popular weight-loss and diabetes medicine are becoming available to Canadian patients.

• •Canada approved a second generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic

Novo Nordisk's oral form of Ozempic (a GLP-1 peptide drug for type 2 diabetes) has FDA approval and will soon be available in the United States. This is the first FDA-approved pill version of a GLP-1 peptide medication for adults with type 2 diabetes.

• •FDA approved Novo Nordisk's oral Ozempic for adults with type 2 diabetes
• •Positioned as the only FDA-approved oral peptide GLP-1 for T2D
• •US launch imminent per Novo Nordisk

Novo Nordisk's oral version of Ozempic (a GLP-1 peptide drug used for type 2 diabetes) will become available in the United States soon. This is the only FDA-approved pill form of this type of medication for adults with diabetes.

• •Novo Nordisk's oral Ozempic to become available in the US soon
• •Only FDA-approved oral peptide GLP-1 for adults with type 2 diabetes

Novo Nordisk is making Ozempic tablets (semaglutide) available across the United States starting May 4. This is a pill version of the weight-loss and diabetes drug that was previously only available as an injection.

• •Novo Nordisk to make Ozempic tablets (semaglutide) available across the US starting May 4
• •Pill version of a drug previously available only as an injection

The FDA is stepping up enforcement actions against pharmacies that make cheaper copycat versions of GLP-1 weight-loss drugs like tirzepatide and semaglutide. The agency is tightening rules on which ingredients pharmacies can legally compound without brand-name drug company approval.

• •FDA stepping up enforcement against pharmacies compounding GLP-1 copycats
• •Action targets compounded tirzepatide and semaglutide
• •Agency tightening rules on ingredients pharmacies can compound without brand approval

Dr. Reddy's has received approval to sell a generic version of semaglutide (Ozempic), a popular weight-loss and diabetes drug. The article indicates pricing information for this generic option will be available, potentially offering a lower-cost alternative to the brand-name version.

• •Dr Reddy's received approval to sell a generic version of semaglutide (Ozempic)
• •Generic launch positioned as lower-cost alternative to brand-name Ozempic

Dr. Reddy's Laboratories received approval from Health Canada (the Canadian health regulator) to sell a generic version of semaglutide injection in 2 mg and 4 mg pen formats. This approval means Canadians will have access to a cheaper copy of this popular weight-loss and diabetes drug.

• •Health Canada approved Dr. Reddy's generic semaglutide injection
• •Approval covers 2 mg and 4 mg pen formats

Novo Nordisk's oral version of Ozempic (semaglutide) is becoming available at pharmacies. The company is reporting earnings this week, and investors are watching closely to see how well the pill form performs.

• •Novo Nordisk's oral version of Ozempic (semaglutide) is reaching pharmacies
• •Novo Nordisk reports earnings this week
• •Investor focus is on early performance of the oral format

The FDA is considering restricting pharmacies' ability to make cheaper compounded copies of weight-loss drugs like semaglutide. This could force patients to buy the more expensive brand-name versions instead.

• •FDA weighing restrictions on pharmacy compounding of weight-loss drugs
• •Semaglutide named as a targeted compounded product
• •Patients could be pushed to higher-priced brand-name versions

• •Novo Nordisk is rebranding its diabetes pill under the Ozempic name

Novo Nordisk is giving its diabetes pill a new name in the United States—it will now be called Ozempic, the same name as the company's popular injectable weight-loss drug. This name change helps patients and doctors recognize that both the pill and injection contain the same active ingredient (semaglutide) and work the same way.

• •Novo Nordisk rebranding its oral diabetes tablet as Ozempic in the US
• •Pill and injection share semaglutide as active ingredient